Department of Obstetrics and Gynecology, Sorlandet Hospital HF, Kristiansand, Norway.
Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Acta Obstet Gynecol Scand. 2024 Jan;103(1):153-164. doi: 10.1111/aogs.14702. Epub 2023 Oct 30.
Approximately 25%-43% of all vulvar carcinomas are associated with human papillomavirus (HPV). In many countries, vulvar carcinoma incidence rates are increasing, possibly due to greater HPV exposure. However, studies exploring changes in HPV prevalence and genotype distribution in vulvar carcinoma over time are scarce. Our aim was to evaluate time trends in HPV prevalence and genotype distribution in vulvar squamous cell carcinoma in an unselected, nationwide sample of Norwegian women. Further, we explored clinical and histopathological aspects in relation to HPV status and investigated whether HPV status was associated with survival.
All vulvar squamous cell carcinoma cases from 1970-1975 and 2000-2005 were extracted from the Cancer Registry of Norway and corresponding tissue blocks were retrieved. After detailed histology review, HPV testing was conducted using real-time TaqMan PCR. Overall survival rates were calculated using the Kaplan-Meier method. Multivariable Cox regression analysis was performed to estimate hazard ratios adjusted for age at diagnosis, stage and diagnostic period.
Histological review was performed on 352 vulvar squamous cell carcinoma cases. We were able to obtain valid HPV analysis results for 282 cases, Overall, 29.8% (95% CI 24.5%-35.5%) of cases were high-risk HPV (hrHPV)-positive. When comparing the two periods, we found that the percentage of hrHPV-positive tumors increased significantly from 23% (95% CI 16.0%-31.4%) in 1970-1975 to 35.3% (95% CI 27.8%-43.3%) in 2000-2005 (P = 0.025). The predominant genotypes were HPV 16 (73%), HPV 33 (21%), and HPV 18 (6%), with similar distributions in both periods. In the more recent cohort, several additional genotypes were detected: HPV 6, 11, 39, 45, 52, 58 and 66 were found in smaller percentages, ranging from 1.8% to 3.6%. In univariate analysis, patients with HPV-positive tumors showed improved overall survival compared with patients with HPV-negative tumors (hazard ratio [HR] 0.65, 95% CI 0.48-0.86).
The prevalence of HPV in vulvar squamous cell carcinomas in Norway was significantly higher in 2000-2005 than in 1970-1975. The three predominant genotypes were HPV 16, 33 and 18 in both time periods. However, several other HPV genotypes have emerged over the last decades. HPV-positivity was associated with better overall survival.
大约 25%-43%的外阴癌与人类乳头瘤病毒(HPV)有关。在许多国家,外阴癌的发病率正在上升,这可能是由于 HPV 暴露的增加。然而,探索 HPV 流行率和基因型分布随时间变化的研究很少。我们的目的是评估 HPV 流行率和基因型分布在外阴鳞状细胞癌中的时间趋势,这是一个未选择的、全国性的挪威女性样本。此外,我们还探讨了与 HPV 状态相关的临床和组织病理学方面,并调查了 HPV 状态是否与生存相关。
从 1970-1975 年和 2000-2005 年的挪威癌症登记处提取所有外阴鳞状细胞癌病例,并检索相应的组织块。经过详细的组织学复习,使用实时 TaqMan PCR 进行 HPV 检测。使用 Kaplan-Meier 方法计算总生存率。多变量 Cox 回归分析用于估计调整诊断时年龄、分期和诊断期的危险比。
对 352 例外阴鳞状细胞癌病例进行了组织学复习。我们能够对 282 例获得有效的 HPV 分析结果。总体而言,29.8%(95%CI 24.5%-35.5%)的病例为高危 HPV(hrHPV)阳性。比较两个时期,我们发现 hrHPV 阳性肿瘤的百分比从 1970-1975 年的 23%(95%CI 16.0%-31.4%)显著增加到 2000-2005 年的 35.3%(95%CI 27.8%-43.3%)(P=0.025)。主要基因型为 HPV 16(73%)、HPV 33(21%)和 HPV 18(6%),两个时期的分布相似。在最近的队列中,检测到了几种额外的基因型:HPV 6、11、39、45、52、58 和 66 的检出率较低,范围为 1.8%-3.6%。在单变量分析中,HPV 阳性肿瘤患者的总生存率优于 HPV 阴性肿瘤患者(风险比[HR]0.65,95%CI 0.48-0.86)。
挪威外阴鳞状细胞癌中 HPV 的流行率在 2000-2005 年明显高于 1970-1975 年。两个时期的三种主要基因型均为 HPV 16、33 和 18。然而,过去几十年出现了其他几种 HPV 基因型。HPV 阳性与总体生存率的提高有关。